GILD
🟢 Gilead Sciences Inc is trading 2.02% up today after FDA accepts its once-weekly HIV PrEP filing for Yeztugo
Gilead Sciences Inc is trading at $126.81 (+2.02%) today after the FDA accepted its supplemental New Drug Application (sNDA) for Yeztugo (lenacapavir) as a...